bufalin has been researched along with Epithelial Ovarian Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dou, H; Su, S; Wang, Z; Zhang, Q | 1 |
| Ao, Y; Ma, Q; Tong, L; Wang, K; Wang, Y; Zhang, H | 1 |
2 other study(ies) available for bufalin and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
Bufalin inhibits ovarian carcinoma via targeting mTOR/HIF-α pathway.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bufanolides; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice, Nude; Neoplasm Invasiveness; Ovarian Neoplasms; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Long noncoding RNA NORAD is upregulated in epithelial ovarian cancer and its downregulation suppressed cancer cell functions by competing with miR-155-5p.
Topics: Animals; Bufanolides; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Mice; MicroRNAs; Neoplasm Transplantation; Ovarian Neoplasms; RNA, Long Noncoding; Up-Regulation | 2019 |